Exceptional Sales Growth in 2024
In 2024, Novonesis showcased remarkable progress with an organic pro forma sales growth of 8% and an adjusted EBITDA margin reaching 36.1%. This strong performance is a testament to the company’s robust business strategies and diverse portfolio in sustainable biosolutions.
Financial Highlights for the Year
Novonesis's pro forma sales for the year amounted to EUR 3,945.5 million, demonstrating an organic growth of 8% despite currency fluctuations impacting the overall figure. The earnings showcased an impressive increase in adjusted EBITDA margin, which rose by 230 basis points to hit 36.1%. This reflects a well-prepared response to market dynamics and a commitment to enhancing shareholder value.
Categories Driving Growth
The company’s divisions made significant contributions to this growth. The Food & Health Biosolutions segment recorded a 7% organic growth, generating pro forma sales of EUR 1,770.9 million. Remarkably, the Planetary Health Biosolutions segment showed even higher momentum, with a pro forma organic sales growth of 9%, resulting in EUR 2,174.6 million in sales.
Looking Ahead: 2025 Expectations
As Novonesis looks toward 2025, expectations remain high. The company is forecasting an organic sales growth between 5% and 8%, with prospective EBITDA margin improvements anticipated to reach between 37% and 38%. These projections reflect a solid foundation built on the successes of the previous year and a keen focus on strategic initiatives.
Commitment to Innovation
Throughout the year, Novonesis launched 45 new innovations, a clear indicator of its ongoing commitment to research, development, and meeting consumer needs across various sectors. This commitment not only enhances the product portfolio but also addresses sustainability challenges worldwide.
Management Insights and Future Stability
Ester Baiget, President & CEO, expressed her satisfaction with the annual results, highlighting the successful integration of two companies into the Novonesis framework. This integration has been crucial for maintaining flexibility and responsiveness in the marketplace. Baiget emphasized that the company is well-positioned to navigate global uncertainties while continuing its path of growth.
Strategic Shareholder Returns
In addition to overall business growth, the company announced a proposed dividend of DKK 4.20 per share (EUR 0.56), maintaining total payouts similar to the previous year, showcasing its dedication to returning value to shareholders. Furthermore, a substantial share buyback program worth EUR 100 million is also on the horizon for 2025.
Conclusion
Overall, the operational success, innovative strides, and commitment to sustainability have established Novonesis as an industry leader poised for continued growth. With a solid outlook for 2025, the company is determined to achieve new heights in both market position and performance metrics.
Frequently Asked Questions
What were Novonesis's sales growth figures for 2024?
Novonesis achieved an organic pro forma sales growth of 8% in 2024.
What is the adjusted EBITDA margin for Novonesis in 2024?
The adjusted EBITDA margin reached 36.1% for the fiscal year 2024.
How many innovations did Novonesis launch in 2024?
Novonesis launched a total of 45 new innovations during the year.
What is the expected sales growth for Novonesis in 2025?
The company expects organic sales growth between 5% and 8% for 2025.
What is the proposed dividend amount for Novonesis shareholders?
The proposed dividend is DKK 4.20 per share, equivalent to EUR 0.56.
